Barclays analyst Carter Gould downgrades Applied Therapeutics (NASDAQ:APLT) from Overweight to Equal-Weight and lowers the price target from $44 to $7.
Gainers
Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
Toward the end of trading Monday, the Dow traded up 0.43% to 36,496.18 while the NASDAQ rose 0.93% to 15,790.97. The S&P also rose, gaining 0.43% to 4,786.68.